Charles Schwab Investment Management Inc Adagio Therapeutics, Inc. Transaction History
Charles Schwab Investment Management Inc
- $429 Billion
- Q1 2024
A detailed history of Charles Schwab Investment Management Inc transactions in Adagio Therapeutics, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 311,254 shares of ADGI stock, worth $1.03 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
311,254
Previous 303,915
2.41%
Holding current value
$1.03 Million
Previous $1.01 Million
2.49%
% of portfolio
0.0%
Previous 0.0%
Shares
11 transactions
Others Institutions Holding ADGI
# of Institutions
92Shares Held
64MCall Options Held
828KPut Options Held
23.4K-
Lee Ainslie Maverick Capital LTD | Dallas, Tx11.8MShares$38.9 Million0.77% of portfolio
-
Deep Track Capital, LP Greenwich, CT11MShares$36.3 Million1.2% of portfolio
-
M28 Capital Management LP Stamford, CT9.25MShares$30.6 Million28.73% of portfolio
-
Alphabet Inc. Mountain View, CA4.53MShares$15 Million0.66% of portfolio
-
Slate Path Capital LP New York, NY3.74MShares$12.4 Million0.25% of portfolio
About Adagio Therapeutics, Inc.
- Ticker ADGI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 108,831,000
- Market Cap $505M
- Description
- Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is the ADG20 (adintrevimab), a neutralizing antibody that is in Phase 3 clinical trials for the treatmen...